PodcastsCiênciaHCPLive Podcasts

HCPLive Podcasts

HCPLive.com
HCPLive Podcasts
Último episódio

246 episódios

  • HCPLive Podcasts

    Joint Ventures: Lupus Health Inequalities, Growing Burden of ICI-Arthritis at EULAR 2026

    26/06/2026 | 13min
    In this episode of Joint Ventures, host Rihards Buss, MD, consultant rheumatologist, Freeman Hospital, Newcastle, sits down with Sarah Dyball, MBBS, PhD, academic clinical lecturer, Centre for Musculoskeletal Research, University of Manchester, and Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London.
    Click here to watch the episode.
  • HCPLive Podcasts

    Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026

    24/06/2026 | 13min
    The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease.
    On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leeds and a specialist in scleroderma, about the most consequential data emerging from the congress.
    Click here to watch the episode.
  • HCPLive Podcasts

    Joint Ventures: Aiming for Targeted First-Line Therapy in Early RA at EULAR 2026

    24/06/2026 | 7min
    In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology, University of Leeds, was joined at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London by Laurence Duquenne, MD, a rheumatology researcher, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, an investigator on one of the meeting's standout studies to examine whether baseline naïve CD4+ T cell frequency can identify which newly diagnosed patients with rheumatoid arthritis (RA) are unlikely to respond to methotrexate monotherapy, and whether adding a biologic at the outset can close that gap.
    Click here to watch the episode.
  • HCPLive Podcasts

    Joint Ventures: EULAR 2026 Congress Preview

    29/05/2026 | 42min
    In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including: 

    Obesity, Weight Management, and Psoriatic Arthritis Sessions

    Personalized Medicine and Biomarkers in RMDs Sessions

    Fatigue and Quality of Life in Connective Tissue Disease Session

    Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session

    Artificial Intelligence and Pattern Recognition in Rheumatology Sessions

    Axial Imaging in Axial Spondyloarthritis Session

    Head-to-Head Superiority Trials in RA and PsA Sessions

    CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions
  • HCPLive Podcasts

    Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus

    28/05/2026 | 36min
    In the second part of this Joint Ventures episode on B cell therapies in rheumatic disease, hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, return with guest Lucy Carter, MBBS, PhD, to move beyond the question of how to deplete B cells and toward the more conceptually challenging problem of what happens after depletion — and whether ianalumab's dual mechanism of action represents the most rational answer yet developed.
    The episode examines the biologic rationale behind combining rituximab with belimumab, reviews the landmark NEPTUNUS Sjögren disease trials in which ianalumab became the first targeted therapy to meet a phase 3 primary endpoint in the disease, and discusses how emerging therapies may ultimately reshape treatment selection, steroid reduction strategies, and long-term management of autoimmune conditions including Sjögren disease and systemic lupus erythematosus.
Mais podcasts de Ciência
Sobre HCPLive Podcasts
Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.
Site de podcast

Ouça HCPLive Podcasts, Ciência Sem Fim e muitos outros podcasts de todo o mundo com o aplicativo o radio.net

Obtenha o aplicativo gratuito radio.net

  • Guardar rádios e podcasts favoritos
  • Transmissão via Wi-Fi ou Bluetooth
  • Carplay & Android Audo compatìvel
  • E ainda mais funções